agriQ Quest Ltd Presentation to Joint Committee of Experts on - - PowerPoint PPT Presentation

agriq quest ltd
SMART_READER_LITE
LIVE PREVIEW

agriQ Quest Ltd Presentation to Joint Committee of Experts on - - PowerPoint PPT Presentation

agriQ Quest Ltd Presentation to Joint Committee of Experts on Tetanus Toxoid Vaccine Testing 23 rd January 2015 About Us Background The Ministry of Health and Catholic Health Commission established a joint committee to investigate the


slide-1
SLIDE 1

agriQ Quest Ltd

About Us

Presentation to Joint Committee of Experts on Tetanus Toxoid Vaccine Testing 23rd January 2015

slide-2
SLIDE 2

Background

The Ministry of Health and Catholic Health Commission established a joint committee to investigate the safety of the tetanus toxoid vaccine administered in the last Kenyan

About Us

vaccine administered in the last Kenyan vaccination campaigns agriQ Quest Ltd was appointed by the joint committee of experts to carry out analysis on selected vials of the tetanus toxoid vaccines

slide-3
SLIDE 3

Objective of the Assessment

  • Analyze content of the vials sampled for the presence of

beta human chorionic gonadotropin hormone (βhCG)

  • Quantify the levels of (βhCG) for each of the samples

where present

About Us

where present

  • Full toxicological analysis of the vaccine, identify any other

substances present, apart from the immunogen, detoxicant and diluents

  • Production of a written report - to include procedure for

analysis, relevant references applied to the analysis, citing publications

  • To inform and interpret to the joint committee of experts

the findings from the Laboratory analysis

slide-4
SLIDE 4

Execution of the Assessment

Sampling and Sample Submission

Lot 1 - 10th Dec. 2014 at KEPI

  • 14 samples collected

About Us

Lot 2 - 17th Dec. 2014 at Upper Hill Medical Center - 4 samples collected Lot 3 - Matching samples submitted to Laboratory - 40 samples

slide-5
SLIDE 5

Objective of the Assessment

Further instructions from the Pharmacy and Poisons Board on 17th Dec. 2014 directed the Laboratory to restrict its initial investigation to:

About Us

investigation to:

Determining if (βhCG) was present in the submitted vials Quantity of (βhCG) present in each of the vials tested [this objective later abandoned].

slide-6
SLIDE 6

Analysis Method and Equipment

Equipment

  • Shimadzu Class VP 10 HPLC equipment

Method

About Us

Method

  • Rapid isolation of hCG using anion exchange

chromatography

  • Retention time for the hCG peak - 35mins
slide-7
SLIDE 7

Typical hCG Chromatogram

About Us

slide-8
SLIDE 8

Laboratory Results - TT vaccine AQ 42905

About Us

slide-9
SLIDE 9

Laboratory Results - TT Vaccine AQ 42906

About Us

slide-10
SLIDE 10

Laboratory Results - TT Vaccine AQ 42915

About Us

slide-11
SLIDE 11

Laboratory Results - TT Vaccine AQ 42916

About Us

slide-12
SLIDE 12

Laboratory Results - Calibration Data Urine 9 wks pregnancy

About Us

slide-13
SLIDE 13

Laboratory Results - Calibration Data Urine 24 wks pregnancy

About Us

slide-14
SLIDE 14

Conclusions from the Analysis

Three samples of B.Nos. 019L3001B & 019L3001C found to contain βhCG Matching vials submitted did not contain βhCG βhCG present in the vials-chemically linked

About Us

βhCG present in the vials-chemically linked Assay for βhCG in its pure form will not produce such a chromatogram as hCG will be metabolized Assay for βhCG that is chemically bonded shows modification in the chromatogram